HomeNewsBusinessStocksBuy Aurobindo Pharma; tgt of Rs 1630: Fairwealth Securities
Trending Topics
Sensex Live
IPOs This Week
Union Budget 2026
Silver Trends in 2026
Gold Rate Today

Buy Aurobindo Pharma; tgt of Rs 1630: Fairwealth Securities

Fairwealth Securities is bullish on Aurobindo Pharma and has recommended buy rating on the stock with a target of Rs 1630 in its January 6, 2011 research report.

January 07, 2011 / 14:07 IST
Story continues below Advertisement
Remove Ad

Fairwealth Securities is bullish on Aurobindo Pharma and has recommended buy rating on the stock with a target of Rs 1630 in its January 6, 2011 research report.

Read More

first published: Jan 7, 2011 01:57 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin youtube
Trending Topics
Sensex Today Gujarat Kidney share price ITR Refund Delay Khaleda Zia Gold Rate Today Silver Price Today Bitcoin Price BMC Elections Amit Shah Delhi Fog
News
Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups
Markets
Home Currencies Commodities Pre-Market IPO Global Market Bonds
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker New Fixed Deposits Fixed Deposit Comparison Fixed Income
Mutual Funds
Home MC 30 Top Ranked Funds ETFs Mutual Fund Screener
Tools
Income Tax Calculator EMI Calculator Retirement Planning Gratuity Calculator Petrol Price in India Diesel Price in India IFSC Code
Community
Stock Markets
Network 18 Sites
News18 Firstpost CNBC TV18 News18 Hindi Cricketnext Overdrive
Quick Links
About Us Contact Us Advisory Alert Advertise with Us Disclaimer Privacy Policy Cookie Policy Terms & Conditions Financial Terms (Glossary) Sitemap Investors
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.